# Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism

> **NCT06293950** · PHASE1 · RECRUITING · sponsor: **University of Jordan** · enrollment: 14 (estimated)

## Conditions studied

- Autism

## Interventions

- **BIOLOGICAL:** WJMSC

## Key facts

- **NCT ID:** NCT06293950
- **Lead sponsor:** University of Jordan
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-09
- **Primary completion:** 2026-06
- **Final completion:** 2027-12
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2025-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06293950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06293950, "Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06293950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*